MX351453B - Composiciones de liberacion sostenida a base de lipidos anfipaticos. - Google Patents

Composiciones de liberacion sostenida a base de lipidos anfipaticos.

Info

Publication number
MX351453B
MX351453B MX2014006271A MX2014006271A MX351453B MX 351453 B MX351453 B MX 351453B MX 2014006271 A MX2014006271 A MX 2014006271A MX 2014006271 A MX2014006271 A MX 2014006271A MX 351453 B MX351453 B MX 351453B
Authority
MX
Mexico
Prior art keywords
sustained release
release compositions
amphipathic lipid
based sustained
amphipathic
Prior art date
Application number
MX2014006271A
Other languages
English (en)
Spanish (es)
Other versions
MX2014006271A (es
Inventor
A Howard Scott
Purvis Troy
Original Assignee
Pegasus Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pegasus Laboratories Inc filed Critical Pegasus Laboratories Inc
Publication of MX2014006271A publication Critical patent/MX2014006271A/es
Publication of MX351453B publication Critical patent/MX351453B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014006271A 2011-12-02 2012-11-30 Composiciones de liberacion sostenida a base de lipidos anfipaticos. MX351453B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566279P 2011-12-02 2011-12-02
PCT/US2012/067361 WO2013082470A1 (en) 2011-12-02 2012-11-30 Amphipathic lipid-based sustained release compositions

Publications (2)

Publication Number Publication Date
MX2014006271A MX2014006271A (es) 2014-09-22
MX351453B true MX351453B (es) 2017-10-16

Family

ID=48524178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006271A MX351453B (es) 2011-12-02 2012-11-30 Composiciones de liberacion sostenida a base de lipidos anfipaticos.

Country Status (8)

Country Link
US (1) US9248096B2 (https=)
EP (1) EP2785333A4 (https=)
JP (1) JP2015500241A (https=)
AU (1) AU2012345726B2 (https=)
BR (1) BR112014013175B1 (https=)
CA (1) CA2854054C (https=)
MX (1) MX351453B (https=)
WO (1) WO2013082470A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP3349735A4 (en) * 2015-09-16 2019-05-15 Corr-Jensen Inc. MULTI-PHASE RELEASE OF SPORTING NUTRITION AND ENERGY BEVERAGE COMPOSITIONS THROUGH LIPID PARTICLES
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
HRP20220652T1 (hr) 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
HUE057877T2 (hu) 2015-12-22 2022-06-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
SMT202300097T1 (it) 2017-03-15 2023-05-12 Modernatx Inc Composto e composizioni per il rilascio intracellulare di agenti terapeutici
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US20190110988A1 (en) * 2017-10-17 2019-04-18 Lemulsa Technologies Inc. Delivery System That Utilizes Liposomal or Emulsion Vehicles
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
MX2021005888A (es) 2018-11-26 2021-06-23 Procter & Gamble Preparacion farmaceutica solida que contiene acido lipoico y uso de esta.
AU2020350759A1 (en) 2019-09-19 2022-03-31 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
BR112022004936A2 (pt) 2019-09-19 2022-06-14 Modernatx Inc Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6348226A (ja) * 1986-08-14 1988-02-29 Ono Pharmaceut Co Ltd 徐放性を有する経口投与用固形製剤
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6077534A (en) * 1997-09-02 2000-06-20 Klinge Pharma Gmbh Production of pharmaceutical formulations for treatment of edema and venous disorders
DE19740983A1 (de) 1997-09-18 1999-04-08 Warner Lambert Co N D Ges D St Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten
EP1900283A3 (en) 1998-03-23 2010-02-10 General Mills, Inc. Encapsulation of components into edible products
EP1183014B1 (en) * 1999-06-14 2003-10-08 Cosmo S.p.A. Controlled release and taste masking oral pharmaceutical compositions
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
PL204079B1 (pl) * 2004-08-12 2009-12-31 Inst Farmaceutyczny Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
CA2678367C (en) 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
WO2010028290A1 (en) * 2008-09-04 2010-03-11 Farnam Companies, Inc. Chewable sustained release formulations
EP2435029B1 (en) * 2009-05-28 2016-12-14 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising tamsulosin

Also Published As

Publication number Publication date
EP2785333A1 (en) 2014-10-08
CA2854054C (en) 2020-05-12
BR112014013175B1 (pt) 2022-08-09
AU2012345726B2 (en) 2017-04-13
US20130142876A1 (en) 2013-06-06
AU2012345726A1 (en) 2014-05-29
US9248096B2 (en) 2016-02-02
BR112014013175A8 (pt) 2021-06-08
BR112014013175A2 (pt) 2017-06-13
NZ624641A (en) 2016-04-29
MX2014006271A (es) 2014-09-22
CA2854054A1 (en) 2013-06-06
JP2015500241A (ja) 2015-01-05
EP2785333A4 (en) 2015-04-01
WO2013082470A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
MX351453B (es) Composiciones de liberacion sostenida a base de lipidos anfipaticos.
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
DK2788006T3 (en) Biodegradable lipids for the delivery of active agents
SG11201406141UA (en) Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient
AU2014359194A1 (en) Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology
PL3083556T3 (pl) Lipidy i kompozycje lipidowe dla dostarczania środków czynnych
EP2779996C0 (en) DRUG DELIVERY SYSTEM PROVIDING PROLONGED DELIVERY OF BIOACTIVE AGENTS
WO2013177419A3 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
PT3061454T (pt) Composições veterinárias orais parasiticidas compreendendo agentes activos de actuação sistémica, métodos e as suas utilizações
IN2015DN03984A (https=)
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
EP2611847A4 (de) Amphiphil zur solubilisierung schwerlöslicher wirkstoffe
MX2016001422A (es) Composicion farmaceutica de fingolimod.
HUE050945T2 (hu) Gyógyszerforma hatóanyagok nyújtott felszabadítására
IL236466A0 (en) Pharmaceutical composition for the release of active components
MX2013008979A (es) Composiciones para el cuidado oral.
EP2846839A4 (en) FORMULATIONS FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES
ZA201306239B (en) Storage-stable formulation of paracetamol in aqueous solution
IN2015DN04074A (https=)
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
GB201114230D0 (en) Addition copolymers and their use
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent
PL2704698T3 (pl) Postać leku do kontrolowanego uwalniania substancji czynnych
TR201104864A2 (tr) Deksketoprofen içeren suda çözünebilir formülasyonlar.

Legal Events

Date Code Title Description
FG Grant or registration